NASDAQ$TECH
Bio-Techne Corp · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Bio-Techne's Q4 2023 performance was marked by a 5% increase in organic revenue and strategic growth platform success.
Bio-Techne reported a 5% increase in organic revenue for Q4 2023, reaching $301.3 million. The company's Diagnostics and Genomics segment saw a 10% organic growth, driven by strong commercial execution. Strategic growth platforms like ExoDx prostate test and GMP proteins delivered record performance with revenue growth of 68% and 58%, respectively. Bio-Techne also finalized the acquisition of Lunaphore, enhancing its spatial biology franchise.
- Organic revenue increased by 5% to $301.3 million.
- GAAP EPS was $0.47, and adjusted EPS was $0.55.
- Diagnostics and Genomics segment experienced 10% organic growth.
- ExoDx prostate test and GMP proteins showed strong revenue growth of 68% and 58%, respectively.
Headline financials
Revenue & EPS history
Bio-Techne · Revenue · Quarterly
$301M
Revenue by segment
Bio-Techne · $223M total across 1 segment · Q4 2023
- Protein Sciences$223M+2.8%100.0%
Forward guidance
No specific forward guidance was provided in the press release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.8%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.8%
Avg return
30 days after
58%
39 / 67 earnings
Positive
+19.6%
Q3 2024
Best reaction
-9.0%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.0% | -18.3% | -8.1% | |
| Q2 2026 | +4.8% | +1.3% | -16.6% | |
| Q1 2026 | -1.9% | -6.0% | +0.9% | |
| Q3 2025 | +2.2% | +13.0% | +2.0% | |
| Q2 2025 | +3.7% | -3.6% | -11.3% | |
| Q1 2025 | +4.3% | +7.3% | +6.5% | |
| Q4 2024 | -6.4% | -8.5% | -8.8% | |
| Q3 2024 | +19.6% | +20.3% | +22.1% | |
| Q2 2024 | -6.2% | -4.2% | +5.8% | |
| Q1 2024 | -6.7% | +3.7% | +11.1% | |
| Q4 2023 | +2.1% | +3.8% | -9.0% | |
| Q3 2023 | +4.8% | +2.6% | +3.5% | |
| Q2 2023 | -2.6% | -3.5% | -3.7% | |
| Q1 2023 | +0.6% | +2.5% | +16.7% | |
| Q4 2022 | -2.3% | -7.8% | -15.8% | |
| Q3 2022 | +0.7% | -9.5% | -5.3% | |
| Q2 2022 | +11.0% | +8.9% | +11.5% | |
| Q1 2022 | -3.9% | -5.3% | -11.0% | |
| Q4 2021 | -1.0% | -4.7% | +5.4% | |
| Q3 2021 | +1.5% | -0.3% | +1.8% | |
| Q2 2021 | +8.3% | +11.9% | +2.3% | |
| Q1 2021 | +13.2% | +12.4% | +14.8% | |
| Q4 2020 | -3.9% | -4.7% | -10.1% | |
| Q3 2020 | +7.7% | +16.5% | +25.4% | |
| Q2 2020 | -0.3% | -3.0% | -6.4% | |
| Q1 2020 | +0.0% | +0.6% | +6.1% | |
| Q4 2019 | -4.6% | -3.7% | -4.8% | |
| Q3 2019 | +3.0% | +4.8% | -0.7% | |
| Q2 2019 | +5.3% | +3.3% | +7.3% | |
| Q1 2019 | -5.5% | -4.1% | -8.5% | |
| Q4 2018 | +5.0% | +5.8% | +12.8% | |
| Q3 2018 | -2.8% | -1.4% | +0.1% | |
| Q2 2018 | +3.0% | +0.8% | +8.6% | |
| Q1 2018 | +3.8% | +4.6% | +9.0% | |
| Q4 2017 | -1.5% | +1.1% | +3.8% | |
| Q3 2017 | +2.0% | +3.0% | +5.3% | |
| Q2 2017 | -1.0% | +2.3% | +6.2% | |
| Q1 2017 | +0.3% | -1.6% | +4.3% | |
| Q4 2016 | -3.4% | -2.8% | -2.6% | |
| Q3 2016 | +7.1% | — | — | |
| Q2 2016 | +4.9% | — | — | |
| Q1 2016 | -9.0% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | +1.6% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | -2.8% | — | — | |
| Q4 2014 | +0.2% | — | — | |
| Q3 2014 | +8.1% | — | — | |
| Q2 2014 | -4.4% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | +4.1% | — | — | |
| Q3 2013 | +0.4% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | -4.3% | — | — | |
| Q4 2012 | -3.8% | — | — | |
| Q3 2012 | +0.5% | — | — | |
| Q2 2012 | +2.2% | — | — | |
| Q1 2012 | -5.3% | — | — | |
| Q4 2009 | +1.4% | — | — | |
| Q4 2011 | +1.4% | — | — | |
| Q3 2011 | +0.5% | — | — | |
| Q3 2010 | +0.5% | — | — | |
| Q2 2011 | -0.8% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q4 2010 | +0.6% | — | — | |
| Q1 2010 | +0.6% | — | — | |
| Q2 2010 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro